2B4 functions as a co-receptor in human NK cell activation - PubMed (original) (raw)
2B4 functions as a co-receptor in human NK cell activation
S Sivori et al. Eur J Immunol. 2000 Mar.
Free article
Abstract
Natural cytotoxicity receptors (NKp46, NKp44 and NKp300) play a predominant role in human NK cell triggering during natural cytotoxicity. Human 2B4 also induced NK cell activation in redirected killing assays using anti-2B4 monoclonal antibodies (mAb) and murine targets. Since this effect was confined to a fraction of NK cells, this suggested a functional heterogeneity of 2B4 molecules. Here we show that activation via 2B4 in redirected killing against murine targets is strictly dependent upon the engagement of NKp46 by murine ligand (s) on target cells. Thus, NK cell clones expressing high surface density of NKp46 (NKp46bright) were triggered by anti-2B4 mAb, whereas NKp46dull clones were not although they expressed a comparable surface density of 2B4. mAb-mediated modulation of NKp46 molecules in NKp46bright clones had no effect on the expression of 2B4 while it rendered cells unresponsive to anti-2B4 mAb. Finally, anti-2B4 mAb could induce NK cell triggering in NKp46dull clones provided that suboptimal doses of anti-NKp44 or anti-CD16 mAb were added to the redirected killing assay. These results indicate that differences in responses do not reflect a functional heterogeneity of 2B4 but rather depend on the co-engagement of triggering receptors.
Similar articles
- Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.
Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L. Moretta A, et al. Annu Rev Immunol. 2001;19:197-223. doi: 10.1146/annurev.immunol.19.1.197. Annu Rev Immunol. 2001. PMID: 11244035 Review. - X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells.
Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, Franceschini R, Ochs HD, Wolf H, Bonnefoy JY, Biassoni R, Moretta L, Notarangelo LD, Moretta A. Parolini S, et al. J Exp Med. 2000 Aug 7;192(3):337-46. doi: 10.1084/jem.192.3.337. J Exp Med. 2000. PMID: 10934222 Free PMC article. - CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity.
Marcenaro E, Augugliaro R, Falco M, Castriconi R, Parolini S, Sivori S, Romeo E, Millo R, Moretta L, Bottino C, Moretta A. Marcenaro E, et al. Eur J Immunol. 2003 Dec;33(12):3367-76. doi: 10.1002/eji.200324425. Eur J Immunol. 2003. PMID: 14635045 - Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, Catina TL, Campbell KS, Santoli D. Brando C, et al. J Leukoc Biol. 2005 Aug;78(2):359-71. doi: 10.1189/jlb.0604360. Epub 2005 Jun 3. J Leukoc Biol. 2005. PMID: 15937142 - Of mice and men: different functions of the murine and human 2B4 (CD244) receptor on NK cells.
Vaidya SV, Mathew PA. Vaidya SV, et al. Immunol Lett. 2006 Jun 15;105(2):180-4. doi: 10.1016/j.imlet.2006.02.006. Epub 2006 Mar 15. Immunol Lett. 2006. PMID: 16621032 Review.
Cited by
- Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells.
Parodi M, Centonze G, Murianni F, Orecchia P, Andriani F, Roato I, Gardelli C, Balsamo M, Moro M, Taiè G, Pastorino U, Petretto A, Lavarello C, Milione M, Sozzi G, Roz L, Vitale M, Bertolini G. Parodi M, et al. J Immunother Cancer. 2024 Mar 7;12(3):e007895. doi: 10.1136/jitc-2023-007895. J Immunother Cancer. 2024. PMID: 38458638 Free PMC article. - Impact of HIV-1 Vpu-mediated downregulation of CD48 on NK-cell-mediated antibody-dependent cellular cytotoxicity.
Marchitto L, Benlarbi M, Prévost J, Laumaea A, Descôteaux-Dinelle J, Medjahed H, Bourassa C, Gendron-Lepage G, Kirchhoff F, Sauter D, Hahn BH, Finzi A, Richard J. Marchitto L, et al. mBio. 2023 Aug 31;14(4):e0078923. doi: 10.1128/mbio.00789-23. Epub 2023 Jul 5. mBio. 2023. PMID: 37404017 Free PMC article. - Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells.
Meng F, Zhang S, Xie J, Zhou Y, Wu Q, Lu B, Zhou S, Zhao X, Li Y. Meng F, et al. J Hematol Oncol. 2023 Jun 14;16(1):62. doi: 10.1186/s13045-023-01455-z. J Hematol Oncol. 2023. PMID: 37316891 Free PMC article. - Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors.
Whalen KA, Rakhra K, Mehta NK, Steinle A, Michaelson JS, Baeuerle PA. Whalen KA, et al. MAbs. 2023 Jan-Dec;15(1):2208697. doi: 10.1080/19420862.2023.2208697. MAbs. 2023. PMID: 37165468 Free PMC article. Review. - Natural Killer Cell-Based Immunotherapy against Glioblastoma.
Morimoto T, Nakazawa T, Maeoka R, Nakagawa I, Tsujimura T, Matsuda R. Morimoto T, et al. Int J Mol Sci. 2023 Jan 20;24(3):2111. doi: 10.3390/ijms24032111. Int J Mol Sci. 2023. PMID: 36768432 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases